The collaboration will produce both Fabs and IgGs towards the epigenetic targets. While the majority of researchers have been using IgGs, Fabs are gaining acceptance among scientists because they are simpler to manipulate for research purposes, for example for attachment of tags. They are also easier to produce.

Talking about the challenges at the moment for producing antibodies, Dr Susanne Gräslund, project coordinator and biotechnology principal investigator, SGC, pointed out that "Validation of the antibodies is always challenging, especially when attempting to validate them for research applications that require different antibody properties. Another general problem is that antibodies in production can perform differently from batch-to-batch, and therefore reproducibility of research results is not great. With the SGC-Life Technologies antibodies, we produce recombinant antibodies that will be consistent in their properties."

"Validation data and community reviews of the new antibodies may be found on 1DegreeBio.org. The release of these epigenetics-targeted antibodies coincides with the launch of 1DegreeBio's new Epigenetics Portal, where epigenetics researchers can find targets, tools and product data specific to their research."